User login
Release Date: August 1, 2017
Expiration Date: July 31, 2018
Note: This activity is no longer available for credit.
Agenda
Developing New Strategic Goals in PTCL (duration 27:00)
Andrei R. Shustov, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA, USA
PTCL as a Rare Disease: A Case of Overall Survival (duration 19:00)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY, USA
Why Might Response Rates Differ Between the East and West? (duration 17:00)
Kensei Tobinai, MD, PhD
National Cancer Center Hospital
Tokyo, Japan
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the end of the activity, participants should be able to:
- Explain why progression-free survival is important when treating patients with PTCL
- Determine when overall survival is possible
- Describe the challenges of using matched control analysis in PTCL clinical trials
- Discuss why different response rates to therapy for PTCL may be seen in Asian patients versus North American or European patients and define the possible contributing factors
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
This activity explores clinical endpoints in PTCL, the importance of choosing the appropriate ones and the possibility of achieving them. Global and regional differences in PTCL are also explored as they relate to response rates. The presentations highlight the challenges physicians face in treating PTCL patients and recent developments are discussed to help practitioners evaluate the utility of these endpoints in choosing appropriate treatments to improve outcomes in their patients with PTCL.
FACULTY
Faculty
Andrei R. Shustov, MD
Disclosures: Consulting fee: Celgene; BMS
Owen O’Connor, MD, PhD
Disclosures: Consulting fees: Mundipharma; Celgene; Contracted Research: Mundipharma; Spectrum; Celgene; Seattle Genetics; TG Therapeutics; ADCT; Trillium
Kensei Tobinai, MD, PhD
Disclosures: Honoraria: Eisai; HUYA Bioscience International; Janssen; Mundipharma; Takeda; Zenyaku Kogyo; Contracted research: Abbvie; Celgene; Chugai Pharma; Eisai; GlaxoSmithKline; Janssen; Kyowa Hakko Kirin; Mundipharma; Ono Pharmaceutical; SERVIER; Takeda
Permissions
Andrei Shustov presentation
- Slide 7: PTCL Prognosis Is Indicative of Diverse Biology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 8: PTCL: Global Epidemiology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (top half)
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (bottom half)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 10: PTCL Prognosis: Histology x Race (USA)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 12: PTCL Prognosis: Clinical Features (top right side)
- Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved.
- Slide 14: PTCL Prognosis: Molecular Classifiers (left side)
- Republished with permission of the American Society of Hematology, from Parilla Castellar ER, et al. Blood 2014;124:1473-1480
- Slide 14: PTCL Prognosis: Molecular Classifiers (right side)
- Republished with permission of the American Society of Hematology, from Iqbal J, et al. Blood 2014;123:2915-2923
- Slide 17: US Epidemiology of PTCL
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slides 18-19: Romidepsin in Relapsed/Refractory PTCL
- Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
- Slides 20-22, 25: Romidepsin in Elderly Patients
- Shustov A, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma 2017 [Epub ahead of print]. Reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com
- Slides 27-28: Belinostat in Relapsed/Refractory PTCL
- Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Kensei Tobinai presentation
- Slide 7: Overall Survival of ATL Pts in JCOG 9801
- Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: August 1, 2017
Expiration Date: July 31, 2018
Note: This activity is no longer available for credit.
Agenda
Developing New Strategic Goals in PTCL (duration 27:00)
Andrei R. Shustov, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA, USA
PTCL as a Rare Disease: A Case of Overall Survival (duration 19:00)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY, USA
Why Might Response Rates Differ Between the East and West? (duration 17:00)
Kensei Tobinai, MD, PhD
National Cancer Center Hospital
Tokyo, Japan
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the end of the activity, participants should be able to:
- Explain why progression-free survival is important when treating patients with PTCL
- Determine when overall survival is possible
- Describe the challenges of using matched control analysis in PTCL clinical trials
- Discuss why different response rates to therapy for PTCL may be seen in Asian patients versus North American or European patients and define the possible contributing factors
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
This activity explores clinical endpoints in PTCL, the importance of choosing the appropriate ones and the possibility of achieving them. Global and regional differences in PTCL are also explored as they relate to response rates. The presentations highlight the challenges physicians face in treating PTCL patients and recent developments are discussed to help practitioners evaluate the utility of these endpoints in choosing appropriate treatments to improve outcomes in their patients with PTCL.
FACULTY
Faculty
Andrei R. Shustov, MD
Disclosures: Consulting fee: Celgene; BMS
Owen O’Connor, MD, PhD
Disclosures: Consulting fees: Mundipharma; Celgene; Contracted Research: Mundipharma; Spectrum; Celgene; Seattle Genetics; TG Therapeutics; ADCT; Trillium
Kensei Tobinai, MD, PhD
Disclosures: Honoraria: Eisai; HUYA Bioscience International; Janssen; Mundipharma; Takeda; Zenyaku Kogyo; Contracted research: Abbvie; Celgene; Chugai Pharma; Eisai; GlaxoSmithKline; Janssen; Kyowa Hakko Kirin; Mundipharma; Ono Pharmaceutical; SERVIER; Takeda
Permissions
Andrei Shustov presentation
- Slide 7: PTCL Prognosis Is Indicative of Diverse Biology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 8: PTCL: Global Epidemiology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (top half)
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (bottom half)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 10: PTCL Prognosis: Histology x Race (USA)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 12: PTCL Prognosis: Clinical Features (top right side)
- Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved.
- Slide 14: PTCL Prognosis: Molecular Classifiers (left side)
- Republished with permission of the American Society of Hematology, from Parilla Castellar ER, et al. Blood 2014;124:1473-1480
- Slide 14: PTCL Prognosis: Molecular Classifiers (right side)
- Republished with permission of the American Society of Hematology, from Iqbal J, et al. Blood 2014;123:2915-2923
- Slide 17: US Epidemiology of PTCL
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slides 18-19: Romidepsin in Relapsed/Refractory PTCL
- Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
- Slides 20-22, 25: Romidepsin in Elderly Patients
- Shustov A, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma 2017 [Epub ahead of print]. Reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com
- Slides 27-28: Belinostat in Relapsed/Refractory PTCL
- Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Kensei Tobinai presentation
- Slide 7: Overall Survival of ATL Pts in JCOG 9801
- Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Release Date: August 1, 2017
Expiration Date: July 31, 2018
Note: This activity is no longer available for credit.
Agenda
Developing New Strategic Goals in PTCL (duration 27:00)
Andrei R. Shustov, MD
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA, USA
PTCL as a Rare Disease: A Case of Overall Survival (duration 19:00)
Owen A. O’Connor, MD, PhD
Columbia University Medical Center
The New York Presbyterian Hospital
New York, NY, USA
Why Might Response Rates Differ Between the East and West? (duration 17:00)
Kensei Tobinai, MD, PhD
National Cancer Center Hospital
Tokyo, Japan
Provided by:
Original activity supported by an educational grant from:
Spectrum Pharmaceuticals
Learning Objectives
At the end of the activity, participants should be able to:
- Explain why progression-free survival is important when treating patients with PTCL
- Determine when overall survival is possible
- Describe the challenges of using matched control analysis in PTCL clinical trials
- Discuss why different response rates to therapy for PTCL may be seen in Asian patients versus North American or European patients and define the possible contributing factors
Target Audience
Hematologists, oncologists, and other clinicians and scientists with an interest in T-cell lymphoma
Statement of Need
This activity explores clinical endpoints in PTCL, the importance of choosing the appropriate ones and the possibility of achieving them. Global and regional differences in PTCL are also explored as they relate to response rates. The presentations highlight the challenges physicians face in treating PTCL patients and recent developments are discussed to help practitioners evaluate the utility of these endpoints in choosing appropriate treatments to improve outcomes in their patients with PTCL.
FACULTY
Faculty
Andrei R. Shustov, MD
Disclosures: Consulting fee: Celgene; BMS
Owen O’Connor, MD, PhD
Disclosures: Consulting fees: Mundipharma; Celgene; Contracted Research: Mundipharma; Spectrum; Celgene; Seattle Genetics; TG Therapeutics; ADCT; Trillium
Kensei Tobinai, MD, PhD
Disclosures: Honoraria: Eisai; HUYA Bioscience International; Janssen; Mundipharma; Takeda; Zenyaku Kogyo; Contracted research: Abbvie; Celgene; Chugai Pharma; Eisai; GlaxoSmithKline; Janssen; Kyowa Hakko Kirin; Mundipharma; Ono Pharmaceutical; SERVIER; Takeda
Permissions
Andrei Shustov presentation
- Slide 7: PTCL Prognosis Is Indicative of Diverse Biology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 8: PTCL: Global Epidemiology
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (top half)
- Reprinted with permission. © 2008 American Society of Clinical Oncology. All rights reserved.
- Slide 9: PTCL: USA Epidemiology (bottom half)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 10: PTCL Prognosis: Histology x Race (USA)
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slide 12: PTCL Prognosis: Clinical Features (top right side)
- Reprinted with permission. © 2013 American Society of Clinical Oncology. All rights reserved.
- Slide 14: PTCL Prognosis: Molecular Classifiers (left side)
- Republished with permission of the American Society of Hematology, from Parilla Castellar ER, et al. Blood 2014;124:1473-1480
- Slide 14: PTCL Prognosis: Molecular Classifiers (right side)
- Republished with permission of the American Society of Hematology, from Iqbal J, et al. Blood 2014;123:2915-2923
- Slide 17: US Epidemiology of PTCL
- Reprinted with permission. © 2016 American Society of Clinical Oncology. All rights reserved.
- Slides 18-19: Romidepsin in Relapsed/Refractory PTCL
- Reprinted with permission. © 2012 American Society of Clinical Oncology. All rights reserved.
- Slides 20-22, 25: Romidepsin in Elderly Patients
- Shustov A, et al. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma 2017 [Epub ahead of print]. Reprinted by permission of Taylor & Francis Ltd, http://www.tandfonline.com
- Slides 27-28: Belinostat in Relapsed/Refractory PTCL
- Reprinted with permission. © 2015 American Society of Clinical Oncology. All rights reserved.
Kensei Tobinai presentation
- Slide 7: Overall Survival of ATL Pts in JCOG 9801
- Reprinted with permission. © 2007 American Society of Clinical Oncology. All rights reserved.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Hemedicus, the supporter, or Frontline Medical Communications. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.